BTOG Guidance & Responses
Member Login
Sign Up For Free

Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer

BTOG can confirm that NICE has recommended durvalumab within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung cancer (NSCLC) in adults whose cancer:

  • is resectable (tumours 4 cm or over, or node positive) and
  • has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

Durvalumab is only recommended if the company provides it according to the commercial arrangement.


For full details and the documents, please see the NICE website

https://www.nice.org.uk/guidance/indevelopment/gid-ta11197/

Other News from NICE

New guidance recommends Nivolumab to treat resectable NSCLC

BTOG wishes to inform members of a new NICE release that has been published today for nivolumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer.   NICE has recommended nivolumab...

Lorlatinib update

BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended Lorlatinib as an option for ALK-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor. There is a commercial access agreement for...

Durvalumab update

BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Durvalumab, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based...